Association of hyaluronic acid family members (HAS1, HAS2, and HYAL‐1) with bladder cancer diagnosis and prognosis
Open Access
- 19 October 2010
- Vol. 117 (6), 1197-1209
- https://doi.org/10.1002/cncr.25565
Abstract
BACKGROUND: Cancer biomarkers are the backbone for the implementation of individualized approaches to bladder cancer (BCa). Hyaluronic acid (HA) and all 7 members of the HA family, that is, HA synthases (HA1, HA2, HA3), HYAL‐1 hyaluronidase, and HA receptors (CD44s, CD44v, and RHAMM), function in tumor growth and progression. However, the diagnostic and prognostic potential of these 7 HA family members has not been compared simultaneously in any cancer. We evaluated the diagnostic and prognostic potential of HA family members in BCa. METHODS: Using quantitative PCR and immunohistochemistry, expression of HA family members was evaluated in prospectively collected bladder tissues (n = 72); mean and median follow‐up were 29.6 ± 5.3 and 24 months, respectively. Transcript levels were also measured in exfoliated urothelial cells from urine specimens (n = 148). RESULTS: Among the HA family members, transcript levels of the HA synthases, HYAL‐1, CD44v, and RHAMM were 4‐ to 16‐fold higher in BCa tissues than in normal tissues (P < .0001); however, CD44s levels were lower. In univariate and multivariate analyses, tumor stage (P = .003), lymph node invasion (P = .033), HYAL‐1 (P = .019), and HAS1 (P = .027) transcript levels, and HYAL‐1 staining (P = .021) were independently associated with metastasis. Tumor stage (P = .019) and HYAL‐1 (P = .046) transcript levels were also associated with disease‐specific mortality. Although HA synthase and HYAL‐1 transcript levels were elevated in exfoliated urothelial cells from BCa patients, the combined HAS2–HYAL‐1 expression detected BCa with an overall sensitivity of 85.4% and a specificity of 79.5% and predicted BCa recurrence within 6 months (P = .004; RR = 6.7). CONCLUSIONS: HYAL‐1 and HAS1 expression predicted BCa metastasis, and HYAL‐1 expression also predicted disease‐specific survival. Furthermore, the combined HAS2–HYAL‐1 biomarker detected BCa and significantly predicted its recurrence. Cancer 2011. © 2010 American Cancer Society.Keywords
This publication has 64 references indexed in Scilit:
- Antitumor Activity of Hyaluronic Acid Synthesis Inhibitor 4-Methylumbelliferone in Prostate Cancer CellsCancer Research, 2010
- HYAL-1 Hyaluronidase: A Potential Prognostic Indicator for Progression to Muscle Invasion and Recurrence in Bladder CancerEuropean Urology, 2010
- Hyaluronic Acid and HYAL-1 in Prostate Biopsy Specimens: Predictors of Biochemical RecurrenceJournal of Urology, 2009
- Udp‐glucose dehydrogenase as a novel field‐specific candidate biomarker of prostate cancerInternational Journal of Cancer, 2009
- Spontaneous Metastasis of Prostate Cancer Is Promoted by Excess Hyaluronan Synthesis and ProcessingThe American Journal of Pathology, 2009
- Preventive Antibacterial Therapy in Acute Ischemic Stroke: A Randomized Controlled TrialPLOS ONE, 2008
- Effects of Prophylactic Antibiotic Therapy With Mezlocillin Plus Sulbactam on the Incidence and Height of Fever After Severe Acute Ischemic StrokeStroke, 2008
- Interleukin 10, monocytes and increased risk of early infection in ischaemic strokeJournal of Neurology, Neurosurgery & Psychiatry, 2006
- The Early Systemic Prophylaxis of Infection After Stroke StudyStroke, 2005
- Complications After Acute StrokeStroke, 1996